We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic (HOLX) Suffers a Larger Drop Than the General Market: Key Insights
Read MoreHide Full Article
In the latest trading session, Hologic (HOLX - Free Report) closed at $64.14, marking a -1.6% move from the previous day. This move lagged the S&P 500's daily loss of 0.84%. Meanwhile, the Dow experienced a drop of 0.7%, and the technology-dominated Nasdaq saw a decrease of 0.91%.
Coming into today, shares of the medical device maker had gained 14.77% in the past month. In that same time, the Medical sector gained 0%, while the S&P 500 gained 1.44%.
The investment community will be paying close attention to the earnings performance of Hologic in its upcoming release. The company is expected to report EPS of $1.06, unchanged from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $1.01 billion, indicating a 0.39% downward movement from the same quarter last year.
HOLX's full-year Zacks Consensus Estimates are calling for earnings of $4.2 per share and revenue of $4.08 billion. These results would represent year-over-year changes of +2.94% and +1.16%, respectively.
Any recent changes to analyst estimates for Hologic should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.27% decrease. Hologic presently features a Zacks Rank of #4 (Sell).
Looking at its valuation, Hologic is holding a Forward P/E ratio of 15.52. This denotes a discount relative to the industry average Forward P/E of 26.88.
It is also worth noting that HOLX currently has a PEG ratio of 2.39. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Instruments stocks are, on average, holding a PEG ratio of 2.26 based on yesterday's closing prices.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 151, putting it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hologic (HOLX) Suffers a Larger Drop Than the General Market: Key Insights
In the latest trading session, Hologic (HOLX - Free Report) closed at $64.14, marking a -1.6% move from the previous day. This move lagged the S&P 500's daily loss of 0.84%. Meanwhile, the Dow experienced a drop of 0.7%, and the technology-dominated Nasdaq saw a decrease of 0.91%.
Coming into today, shares of the medical device maker had gained 14.77% in the past month. In that same time, the Medical sector gained 0%, while the S&P 500 gained 1.44%.
The investment community will be paying close attention to the earnings performance of Hologic in its upcoming release. The company is expected to report EPS of $1.06, unchanged from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $1.01 billion, indicating a 0.39% downward movement from the same quarter last year.
HOLX's full-year Zacks Consensus Estimates are calling for earnings of $4.2 per share and revenue of $4.08 billion. These results would represent year-over-year changes of +2.94% and +1.16%, respectively.
Any recent changes to analyst estimates for Hologic should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.27% decrease. Hologic presently features a Zacks Rank of #4 (Sell).
Looking at its valuation, Hologic is holding a Forward P/E ratio of 15.52. This denotes a discount relative to the industry average Forward P/E of 26.88.
It is also worth noting that HOLX currently has a PEG ratio of 2.39. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Instruments stocks are, on average, holding a PEG ratio of 2.26 based on yesterday's closing prices.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 151, putting it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.